Related Experiment Videos

Dequalinium induces a selective depletion of mitochondrial DNA from HeLa human cervical carcinoma cells

K R Schneider Berlin1, C V Ammini, T C Rowe

  • 1Department of Pharmacology and Therapeutics, University of Florida College of Medicine, Gainesville, Florida, 32610-0267, USA.

Experimental Cell Research
|November 26, 1998
PubMed

Insights

The anticancer drug dequalinium (DEQ) inhibits cervical cancer cell growth by depleting mitochondrial DNA (mtDNA). This loss disrupts essential mitochondrial functions, leading to cell death and demonstrating DEQ

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • Dequalinium (DEQ) is an anticancer drug with a known impact on cell growth.
  • Mitochondrial DNA (mtDNA) encodes essential proteins for cellular respiration.

Purpose of the Study:

  • To investigate the mechanism by which dequalinium (DEQ) inhibits human cervical carcinoma cell growth.
  • To determine the role of mitochondrial DNA (mtDNA) in DEQ-induced cytotoxicity.

Main Methods:

  • Treatment of cultured human cervical carcinoma cells with DEQ.
  • Measurement of cell growth, mitochondrial DNA (mtDNA) levels, cytochrome c oxidase activity, and lactate production.
  • Assessment of cellular resistance to DEQ under conditions bypassing mtDNA-encoded functions.

Main Results:

  • DEQ treatment caused delayed cell growth inhibition.
  • Inhibition correlated with loss of mitochondrial DNA (mtDNA), decreased cytochrome c oxidase activity, and increased lactate.
  • Cells bypassed DEQ effects when mtDNA-independent functions were utilized, independent of drug accumulation.

Conclusions:

  • DEQ-induced depletion of mitochondrial DNA (mtDNA) is a key mechanism underlying its cytotoxic effects.
  • The drug likely inhibits mtDNA synthesis, leading to loss of essential mitochondrial functions and cell death.
  • Targeting mtDNA may be a viable strategy for developing new anticancer therapies.

Related Concept Videos